EE200000355A - IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine - Google Patents

IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine

Info

Publication number
EE200000355A
EE200000355A EEP200000355A EEP200000355A EE200000355A EE 200000355 A EE200000355 A EE 200000355A EE P200000355 A EEP200000355 A EE P200000355A EE P200000355 A EEP200000355 A EE P200000355A EE 200000355 A EE200000355 A EE 200000355A
Authority
EE
Estonia
Prior art keywords
ifnar
ifn
dna
pharmaceutical composition
host cell
Prior art date
Application number
EEP200000355A
Other languages
English (en)
Estonian (et)
Inventor
Tepper Mark
Cunningham Mark
Sherris David
El Tayar Nabil
Mckenna Sean
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000355A publication Critical patent/EE200000355A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200000355A 1997-12-19 1998-12-18 IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine EE200000355A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
PCT/US1998/026926 WO1999032141A1 (en) 1997-12-19 1998-12-18 Ifnar2/ifn complex

Publications (1)

Publication Number Publication Date
EE200000355A true EE200000355A (et) 2001-10-15

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000355A EE200000355A (et) 1997-12-19 1998-12-18 IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine

Country Status (27)

Country Link
US (1) US6372207B1 (es)
EP (1) EP1037658B1 (es)
JP (1) JP4601163B2 (es)
KR (1) KR100593981B1 (es)
CN (1) CN1241638C (es)
AR (1) AR020315A1 (es)
AT (1) ATE218362T1 (es)
AU (1) AU755078B2 (es)
BG (1) BG64920B1 (es)
BR (1) BR9813753A (es)
CA (1) CA2311648C (es)
DE (1) DE69805844T2 (es)
DK (1) DK1037658T3 (es)
EA (1) EA003635B1 (es)
EE (1) EE200000355A (es)
ES (1) ES2174530T3 (es)
HU (1) HUP0100456A3 (es)
IL (2) IL136855A0 (es)
NO (1) NO20002691L (es)
NZ (1) NZ504771A (es)
PL (1) PL197568B1 (es)
PT (1) PT1037658E (es)
SK (1) SK9222000A3 (es)
TR (1) TR200001961T2 (es)
UA (1) UA74132C2 (es)
WO (1) WO1999032141A1 (es)
ZA (1) ZA9811634B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
JP4850514B2 (ja) * 2003-08-25 2012-01-11 東レ株式会社 インターフェロンβ複合体
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
WO2014151422A1 (en) * 2013-03-15 2014-09-25 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CA3067539A1 (en) * 2017-06-20 2018-12-27 The Board Of Regents Of The University Of Texas System Interferon prodrug for the treatment of cancer
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821078A (en) 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
IL136855A0 (en) 2001-06-14
UA74132C2 (uk) 2005-11-15
ATE218362T1 (de) 2002-06-15
IL136855A (en) 2007-07-24
PL197568B1 (pl) 2008-04-30
NO20002691D0 (no) 2000-05-25
NO20002691L (no) 2000-08-18
DE69805844D1 (de) 2002-07-11
AU755078B2 (en) 2002-12-05
BR9813753A (pt) 2000-10-10
AU1926999A (en) 1999-07-12
ES2174530T3 (es) 2002-11-01
WO1999032141A1 (en) 1999-07-01
HUP0100456A1 (hu) 2001-06-28
PL341423A1 (en) 2001-04-09
CA2311648A1 (en) 1999-07-01
US6372207B1 (en) 2002-04-16
BG64920B1 (bg) 2006-09-29
PT1037658E (pt) 2002-10-31
NZ504771A (en) 2002-09-27
HUP0100456A3 (en) 2003-09-29
EA003635B1 (ru) 2003-08-28
CN1241638C (zh) 2006-02-15
DE69805844T2 (de) 2002-10-24
ZA9811634B (en) 1999-06-22
SK9222000A3 (en) 2001-01-18
BG104539A (en) 2001-04-30
JP4601163B2 (ja) 2010-12-22
KR20010032836A (ko) 2001-04-25
CA2311648C (en) 2010-11-16
EA200000685A1 (ru) 2000-12-25
CN1282255A (zh) 2001-01-31
TR200001961T2 (tr) 2000-11-21
AR020315A1 (es) 2002-05-08
JP2001526242A (ja) 2001-12-18
HK1032914A1 (en) 2001-08-10
KR100593981B1 (ko) 2006-06-30
EP1037658B1 (en) 2002-06-05
DK1037658T3 (da) 2002-09-30
EP1037658A1 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
EE200000355A (et) IFN/IFNAR kompleks ja vastav molekul ning nende kasutamine, DNA, peremeesrakk, liitvalgu valmistamismeetod, I tüüpi IFN säilimisaja pikendamise meetod, farmatseutiline kompositsioon ja IFNAR kasutamine
EE200000151A (et) Aminoterminaalselt kärbitud rantes vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
FI962247A7 (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden kä yttömenetelmät
PL324328A1 (en) Novel nucleic acid construct, method of obtaining same, application thereof, method of manufacturing a pharmaceutic agent, method of producing cells, method of producing protein and pharmaceutic agent as such
NO20010277D0 (no) Benzocykloheptener, fremgangsmåte for fremstilling derav, farmasöytiske preparater inneholdende disse, og deres anvendelse for fremstilling av medikamenter
DE69731646D1 (de) Verabreichung von nukleinsäurepartikeln
FR2723951B1 (fr) Peptide, agent antibacterien contenant ce peptide, gene de ce peptide, adn recombine contenant ce gene et procede de preparation de ce peptide.
IT1291366B1 (it) Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
FI971100L (fi) Menetelmä yhdistelmä-DNA-proteiinien, plasmidien ja modifioitujen solujen tuottamiseksi
EE200100173A (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
CA2032167A1 (en) Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene
EP1071749A4 (en) NUCLEIC ACID AND LRSG PROTEIN MOLECULES AND USES THEREOF
BR9606521A (pt) Polinucleotídeo purificado e isolado molécula de dna construção de expressão de dna célula hospedeira método para produzir um polipeptídeo humano polipeptídeo purificado e isolado anticorpo e linhagem celular de hibridoma
EP0676413A3 (en) Interferon alpha / beta binding protein, its production and application.
DE60009858D1 (de) Hydrolysate aus Proteinen von Schwämmen und Verfahren zur deren Herstellung
EE200000336A (et) Ehhinokandiini derivaadid, nende valmistamismeetod, vaheühendid ja farmatseutilised kompositsioonid
DE69738977D1 (de) Neues fusionsprotein, dafuer kodierendes gen, rekoerwendung
FR2761992B1 (fr) Nouveaux steroides 4-halogenes, leur procede et intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
WO2000043510A3 (en) Ras activator nucleic acid molecules - guanine nucleotide releasing factor grf4, polypeptides and methods of use
EE200000356A (et) DNA molekul, mis kodeerib mutantset prepro-neuropeptiidi Y, mutantne signaalpeptiid ja nende kasutamine
PT83688B (pt) Processo de preparacao de uma molecula de adn, de um polipeptido e de composicao farmaceutica contendo-o
DE60230594D1 (de) Fusionsprotein mit beta-1,2-n-acetylglucosaminyl-transferase-ii-aktivität und herstellungsverfahren dafür

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner